Rituximab (Anti Cd20 Antibody) Based Therapy : A Holy Grail for Both Heamatological and Non Haematological Disorders
نویسنده
چکیده
Uses : = Low-grade or follicular CD20-positive non-Hodgkin’s lymphoma = Follicular CD20-positive non-Hodgkin's lymphoma = Low-grade or follicular CD20-positive non-Hodgkin’s lymphoma = CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma = CD20-positive chronic lymphocytic leukemia, Mantle cell lymphoma. = Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) = Burkitts lymphoma = Relapsed ALL (CD20+) ABSTRACT
منابع مشابه
Rituximab and Other New Anti-cd20 Mabs for Non-hodgkin’s Lymphoma Treatment
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells. CD20 represents a good target for NHL immunotherapy because it is largely expressed on B cell NHL and not on B cell precursors and plasma cells. The anti-CD20 monoclonal antibody (mAb) rituxim...
متن کاملPhysicochemical evaluation of lyophilized formulation of p-SCN-Bn-DOTA-and p-SCN-Bn-DTPA-rituximab for NHL radioimmunotherapy
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radioimmunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic ...
متن کاملPhysicochemical evaluation of lyophilized formulation of p-SCN-Bn-DOTA-and p-SCN-Bn-DTPA-rituximab for NHL radioimmunotherapy
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radioimmunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic ...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کامل